Coherus BioSciences, Inc (CHRS): Price-to-Revenue Ratio

Brandmark of Coherus BioSciences, Inc (CHRS)

The stabilization of Coherus Biosciences (CHRS) image in immuno-oncology on GURU.Markets is reflected in this P/S chart, which captures the metric at 1.60. Coherus Biosciences is implementing an aggressive corporate culture with transparent KPIs for clinicians. However, aggressive dumping and patent disputes in the biosimilars sector create significant risks, necessitating a precise alignment of market value with the business's actual revenue.

CHRS Coherus Biosciences P/S Multiple (07/04/2022 - 11/15/2026)

Coherus BioSciences, Inc (CHRS) - metric breakdowns and financial figures

- current quotes and average value forecast:
Summary company analytics:Coherus BioSciences
Mass-produced product of Coherus

Investors are assessing the resilience of Coherus Biosciences (CHRS) through the price-to-sales ratio, which determines the value of every dollar of revenue. By analyzing this price-to-sales chart, one can gauge the market's confidence in the commercial success of LOQTORZI and its biosimilars to avoid the risks of long-term asset impairment under undervalued multiples.